bluebird bio (BLUE) Announces $400M Common Stock Offering
Get Alerts BLUE Hot Sheet
Join SI Premium – FREE
bluebird bio (NASDAQ: BLUE) announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.
BofA Merrill Lynch, Morgan Stanley and Cowen and Company are acting as joint book-running managers of the proposed offering. SunTrust Robinson Humphrey, Wedbush PacGrow and Roth Capital Partners are acting as co-managers. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
- Eli Lilly (LLY) sleep apnea study data seen as a win, stock gains
- Bank of New York Mellon (BK) PT Raised to $66 at BofA Securities
Create E-mail Alert Related Categories
Equity Offerings, Trader TalkRelated Entities
Morgan Stanley, Roth Capital, SunTrust Robinson Humphrey, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!